SHP2
Src homology phosphatase 2; PTPN11
Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 gene, is a 593 amino acid classical non-receptor protein tyrosine phosphatase (PTP). SHP2 is involved in diverse signalling pathways such as RAS-MAPK, PI3K-AKT, JAK-STAT and PD-1/PD-L1. Besides, SHP2 negatively regulates the activation of recombinant NLRP3 (NLR family, pyrin domain containing protein 3) inflammasome via mitochondrial homeostasis. SHP2 has been regarded as an extremely attractive target for human diseases therapies, particular in cancer.
All Product Categories
-
SHP2 関連製品 (115)
関連製品 (115)
-
抗体 (1)
- Ellagic acid (エラグ酸)
-
Batoprotafib
0 Images別名: TNO155
-
Sitneprotafib
0 Images別名: JAB-3312Sitneprotafib (JAB-3312) is an orally effective anticancer phosphatase SHP2 inhibitor (IC50: 1.9 nM) with anti-cancer activity. Sitneprotafib has good tolerability and significantly induced tumor regression in a KYSE-520 mouse xenograft model.
-
SHP2-D26
0 Images製品番号: HY-145162CAS 番号: 2458219-65-1SHP2-D26 is a SHP2 PROTAC degrader with DC50 values of 6.0 nM (KYSE520 cells) and 2.6 nM (MV4;11 cells), respectively. SHP2-D26 inhibits ERK phosphorylation, upregulates Bim levels, downregulates Mcl-1 levels, and induces cell cycle arrest and apoptosis. SHP2-D26 can be used in studies related to esophageal cancer, acute myeloid leukemia and non-small cell lung cancer.
-
(S)-SHP844-NHS
0 Images製品番号: HY-189844(S)-SHP844-NHS is a covalent allosteric, selective SHP2 inhibitor with an IC50 of 15.0 nM and a Ki of 0.037 μM. (S)-SHP844-NHS inhibits DUSP6 mRNA. (S)-SHP844-NHS can be used for research on lung cancer.
-
Illudalic acid
0 Images製品番号: HY-N12776CAS 番号: 18508-77-5Illudalic acid is a sesquiterpenoid natural product discovered in Omphalotus illudens. Illudalic acid inhibits LAR with an IC50 of 2.1 µM, and also inhibits CD45, PTPμ, and SHP2. Illudalic acid derivatives inhibit PTPRD and reduce drug-induced reward behavior in animal models. Illudalic acid can be used in research on LAR-related diseases.
-
NSC-87877
0 ImagesNSC-87877 is a potent inhibitor of Shp2 and Shp1 protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC50 values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits dual-specificity phosphatase 26 (DUSP26).
-
Vociprotafib
0 Images別名: RMC-4630; SHP2-IN-7Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the RAS-RAF-MEK-ERK signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib (HY-15772)-sensitive EGFR-mutant tumors of mice.
-
PF-07284892
0 Images製品番号: HY-153740CAS 番号: 2498597-94-5別名: ARRY-558
- PHPS1 (PHPS1)
-
PTP Inhibitor IV
(PTP Inhibitor IV)
0 ImagesPTP Inhibitor IV is a protein tyrosine phosphatase (PTP) inhibitor that competitively inhibits DUSP14 phosphatase activity with an 50 of 5.21 μM. PTP Inhibitor IV inhibits SHP-2, PTP1B, PTP-ε, PTP Meg-2, PTP-σ, PTP-β, and PTP-μ with 50s of 1.8 μM, 2.5 μM, 8.4 μM, 13 μM, 20 μM, 6.4 μM, and 6.7 μM, respectively.
-
SPI-112
0 ImagesSPI-112 is a potent, selective and competitive SHP2 (PTPN11) inhibitor with IC50s of 1 μM, 18.3 μM and 14.5 μM for SHP2, protein tyrosine phosphatase (PTP) and PTP1B, respectively.
-
IACS-13909
0 ImagesIACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC50 of 15.7 nM and a Kd of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1). IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK)-dependent cancers.
-
Bis(maltolato)oxovanadium(IV)
(Bis(maltolato)oxovanadium(IV))
0 Images別名: BMOVBis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer.
